By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Drugs and Therapies. According to news reporting originating from Jalgaon, India, by NewsRx correspondents, research stated, "With the emergence of multidrug-resistant mycobacterial strains, better therapeutic strategies are required for the successful treatment of the infection. Although antimicrobial peptides (AMPs) and silver nanoparticles (AgNPs) are becoming one of the popular antibacterial agents, their antimycobacterial potential is not fully evaluated."
Our news editors obtained a quote from the research from the School of Life Science, "In this study, we synthesized biogenic-silver nanoparticles using bacterial, fungal, and plant biomasses and analyzed their antibacterial activities in combination with AMPs against mycobacteria. Mycobacterium smegmatis was found to be more susceptible to AgNPs compared to M. marinum. We found that NK-2 showed enhanced killing effect with NP-1 and NP-2 biogenic nanoparticles at a 0.5-ppm concentration, whereas LLKKK-18 showed antibacterial activity only with NP-2 at 0.5-ppm dose against M. smegmatis. In case of M. marinum NK-2 did not show any additive activity with NP-1 and NP-2 and LLKKK-18 alone completely inhibited the bacterial growth. Both NP-1 and NP-2 also showed increased killing of M. smegmatis in combination with the antituberculosis drug rifampin. The sizes and shapes of the AgNPs were determined by transmission electron microscopy and dynamic light scattering. AgNPs showed no cytotoxic or DNA damage effects on macrophages at the mycobactericidal dose, whereas treatment with higher doses of AgNPs caused toxicity and micronuclei formation in cytokinesis blocked cells. Macrophages actively endocytosed fluorescein isothiocyanate-labeled AgNPs resulting in nitric oxide independent intracellular killing of M. smegmatis. Apoptosis and cell cycle studies showed that treatment with higher dose of AgNPs arrested macrophages at the G(1)-phase."
According to the news editors, the research concluded: "In summary, our data suggest the combined effect of biogenic-AgNPs and antimicrobial peptides as a promising antimycobacterial template."
For more information on this research see: Cationic Antimicrobial Peptides and Biogenic Silver Nanoparticles Kill Mycobacteria without Eliciting DNA Damage and Cytotoxicity in Mouse Macrophages. Antimicrobial Agents and Chemotherapy, 2013;57(8):3688-3698. Antimicrobial Agents and Chemotherapy can be contacted at: Amer Soc Microbiology, 1752 N St NW, Washington, DC 20036-2904, USA. (American Society for Microbiology - www.asm.org; Antimicrobial Agents and Chemotherapy - aac.asm.org)
The news editors report that additional information may be obtained by contacting S. Mohanty, North Maharashtra Univ, Sch Life Sci, Jalgaon, India. Additional authors for this research include P. Jena, R. Mehta, R. Pati, B. Banerjee, S. Patil and A. Sonawane (see also Drugs and Therapies).
Keywords for this news article include: Asia, Antibacterial, Antibiotics, Antimicrobials, India, Jalgaon, Peptides, Proteins, Treatment, DNA Damage, Phagocytes, Proteomics, Amino Acids, Macrophages, DNA Research, Nanoparticle, Myeloid Cells, Nanotechnology, Drugs and Therapies, Deoxyribonucleic Acid, Emerging Technologies, Connective Tissue Cells
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC